Biosimilars
29 results
Applied filters
Preparing to use denosumab 60mg biosimilar
1 October 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
1 October 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Biosimilar and key generic medicines – September 2026 update
16 September 2026An update around biosimilar and key generic medicines to support system planning and mobilisation.
Preparing to use ustekinumab biosimilar
31 July 2026Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
31 July 2026Ustekinumab biosimilars are available for use within the NHS. Learn about indications, formulations, supporting evidence and differences.
Preparing to use golimumab biosimilar
21 July 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
Biosimilar insulin: a primary care discussion
1 July 2026A discussion about the considerations of implementing biosimilar insulin in primary care.
Biosimilar and key generic medicines – June 2026 update
25 June 2026An update about biosimilar and key generic medicines to support system planning and mobilisation